Champions strikes deal with Concordia

March 23, 2009

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 18 No 3

Volume 18

Issue 3

Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.

Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.

As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.

Articles in this issue

Genetics opens new window on acute myeloid leukemia

Pralatrexate: Upfront Rx strategy for T-cell lymphoma

Functional MRI boosts early staging of cervical cancer

Unseen bone lesions flare up on post-Rx NSCLC scans

Exercise jumpstarts quality of life in lung ca

Champions strikes deal with Concordia

Oncolytics kicks off reovirus trial

PET/CT picks up additional lesions not found on chest CT

Targeted therapies address hard-to-treat liver tumors

Should ADT be part of care for all patients with intermediate-risk prostate cancer?

ASTRO hosts IT project; ASCO weighs in on stimulus plan

Calculate, negotiate: Pay heed to your non-CMS fees

Breast tissue evaluation with fine-needle aspiration fast tracks cancer Rx planning

Investing in future generationsSharon Murphy, MD, views pediatric oncology as a chance to affect an entire lifetime.

Related Videos

Video 8 - "Closing Thoughts on the Future of NSCLC"

Video 7 - "Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC "

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"

Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"

A panel of 5 experts on liver cancer

Related Content

Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.

Ovarian Cancer Linked to Genital Talcum Powder Use

Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

Related Content

Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.

Ovarian Cancer Linked to Genital Talcum Powder Use

Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Pre-Transplant FLT3-ITD Detection Confers Relapse/Death Risk in AML

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

FDA Grants Breakthrough Therapy Designation to Petosemtamab in HNSCC

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.